Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciMount of Chengdu to Start US Trials of Novel Irritable Bowel Treatment

publication date: May 14, 2020

SciMount Pharmatech, a Chengdu subsidiary of Xiling Lab, has been approved to start US trials of SMP-100 as a treatment for Irritable Bowel Syndrome with diarrhea (IBS-D). SMP-100 is a selective serotonin receptor-3 (5-HT3) partial agonist. Compared to current 5-HT3 IBS drugs, SMP-100 lowers the inhibition of 5-HT3, which is expected to improve the safety effect profile, while it matches the efficacy of available treatments. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital